Attorney Docket No.:

DEX-0142

Inventors:

Macina et al.

Serial No.:

09/802,674

Filing Date:

March 9, 2001

Page 2

) 1. (amended) A method for diagnosing the presence of gastrointest and cancer in a patient comprising:

- (a) determining levels of SEQ 1D NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ D NO: 3 in cells, tissues or bodily fluids in a patient; and
- (b) comparing the determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 with levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 in said patient versus normal human control is associated with the presence of gastrointestinal cancer.
- 2. (amended) A method of diagnosing metastases of gastrointestinal dancer in a patient comprising:
- (a) identifying a patient having gastrointestinal cancer that is not known to have metastasized;
- (b) determining levels of SEQ 1D NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense

Received from < 8568101454 > at 1/21/03 3:09:11 PM (Eastern Standard Time)

AI

Attorney Docket No.:

DEX-0142

Inventors:

Macina et al.

Serial No.:

09/802,674

Filing Date:

March 9, 2001

Page 3

sequence of SEQ ID NO: 3 in a sample of cells, tissues, or bodily fluid from said patient; and

- (c) comparing the determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 with levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 in cells, tissue, or bodily fluid of a normal human control, wherein a decrease in determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 in the patient versus the normal human control is associated with a cancer which has metastasized.
- 3. (amended) A method of staging gastrointestinal cancer in a patient having gastrointestinal cancer comprising:
 - (a) identifying a patient having gastrointestinal cancer;
- (b) determining levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 in a sample of cells, tissue, or bodily fluid from said patient; and
- (c) comparing determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO:3 with levels of SEQ ID NO:3 or

AI

Attorney Docket No.: DEX-0142

Inventors:

Macina et al.

Serial No.: Filing Date: 09/802,674

Page 4

March 9, 2001

a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 in cells, tissues, or bodily fluid of a normal human control, wherein a decrease in determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under\stringent conditions to the antisense sequence of SEQ ID NO: 3 ih said patient versus the normal human control is associated with a cancer which is progressing and an increase in the determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 is associated with a cancer which is regressing or in remission.

- cancer in a patient for the obset of metastasis comprising:
- (a) identifying a patient having gastrointestinal cancer that is not known to have metastasized;
- (b) periodically defermining levels of SEQ ID NO:3 or a polynucleotide which hybr $ar{m{1}}$ dizes under stringent conditions to the antisense sequence of SEQ \uparrow D NO: 3 in samples of cells, tissues, or bodily fluid from said patient; and
- (c) comparing the periodically determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 with levels

Attorney Docket No.: DEX-0142

Inventors: Serial No.: Macina et al. 09/802,674

Filing Date:

March 9, 2001

Page 5

of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequence of SEQ ID NO: 3 in cells, tissues, or bodily fluid of a normal human control, wherein a decrease in any one of the periodically determined levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent condittons to the antisense sequence of SEQ ID NO: 3 in the patient versus the normal human control is associated with a cancer which has hetastasized.

- (amended) A method of monitoring a change in stage of gastrointestinal/cahcer in a patient comprising:
 - (a) identifying\a patient having gastrointestinal cancer;
- (b) periodically determining levels of SEQ ID NO:3 or a polynucleotide which hybridizes under stringent conditions to the antisense sequende of SEQ ID NO: 3 in cells, tissues, or bodily fluid from said patient and
- (c) comparing the periodically determined levels of SEO ID NO:3 or a polynucled tide which hybridizes under stringent conditions to the antisens sequence of SEQ ID NO: 3 with levels of SEQ ID NO:3 or a polynudleotide which hybridizes under stringent conditions to the \antisense sequence of SEQ ID NO: 3 in cells, tissues, or bodily fligid of a normal human control, wherein a decrease in any one of the periodically determined